Article Details

FLX Bio Completes $60 Million Series C Financing

Retrieved on: 2017-12-20 20:56:15

Tags for this article:

Click the tags to see associated articles and topics

FLX Bio Completes $60 Million Series C Financing. View article details on hiswai:

Excerpt

<div>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system against cancer, today announced the completion of a $60 million Series C private financing.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up